What is Bloom Burton’s Estimate for TSE:MBX FY2027 Earnings?

Microbix Biosystems Inc. (TSE:MBX) – Equities researchers at Bloom Burton lowered their FY2027 earnings estimates for shares of Microbix Biosystems in a report issued on Friday, May 16th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of $0.04 per share for the year, down from their previous forecast of $0.05. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share.

Microbix Biosystems Stock Down 2.9%

Shares of TSE MBX opened at C$0.34 on Monday. The firm’s 50-day moving average price is C$0.38 and its 200-day moving average price is C$0.39. The company has a current ratio of 7.15, a quick ratio of 5.57 and a debt-to-equity ratio of 22.61. The stock has a market capitalization of C$44.78 million, a price-to-earnings ratio of 12.95 and a beta of 0.34. Microbix Biosystems has a 12-month low of C$0.29 and a 12-month high of C$0.55.

Insider Activity

In other Microbix Biosystems news, Senior Officer Mark Adrian Luscher sold 70,750 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of C$0.43, for a total value of C$30,295.15. Corporate insiders own 14.00% of the company’s stock.

About Microbix Biosystems

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.